Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.71 |
| ▸ | PDE8B | O95263 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.43 |
| ▸ | PI4KA | P42356 | 3/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20191359 | 0.83 | AHCY (1.00) | AHCYADORA2BADORA2AADORA3 | |
| SCHEMBL21057373 | 0.81 | AHCY (0.53) | AHCYPDE8BADORA2BADORA2AADORA3 | |
| SCHEMBL21057362 | 0.81 | AHCY (0.53) | AHCYPDE8BADORA2BADORA2AADORA3 | |
| SCHEMBL21057371 | 0.81 | AHCY (0.53) | AHCYPDE8BADORA2BADORA2AADORA3 | |
| SCHEMBL21057375 | 0.81 | AHCY (0.53) | AHCYPDE8BADORA2BADORA2AADORA3 | |
| SCHEMBL21057360 | 0.81 | AHCY (0.53) | AHCYPDE8BADORA2BADORA2AADORA3 | |
| SCHEMBL21057391 | 0.81 | AHCY (0.53) | AHCYPDE8BADORA2BADORA2AADORA3 | |
| SCHEMBL21057389 | 0.81 | AHCY (0.53) | AHCYPDE8BADORA2BADORA2AADORA3 | |
| SCHEMBL21057363 | 0.81 | AHCY (0.53) | AHCYPDE8BADORA2BADORA2AADORA3 | |
| SCHEMBL9679135 | 0.80 | AHCY (0.80) | AHCYADORA2BADORA2AADORA3DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | claimed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | AHCY 1944/4885PDE8B 10/4885ADORA2B 3015/4885 |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | AHCY 1959/4885PDE8B 13/4885ADORA2B 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.